IC
EIDX

Ikarian Capital’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Ikarian Capital’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-63,011
Closed -$3.18M – 269
2020
Q3 		$3.18M Sell
63,011
-36,989
-37% -$1.66M 0.23% 89
2020
Q2 		$4.77M Buy
+100,000
New +$4.65M 0.38% 69

Other funds holding EIDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Ikarian Capital's EIDX Position: Q4 2020 in Review

Ikarian Capital sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2020, closing a stake of 63,011 shares — an estimated $3.18M sold.

Ikarian Capital first reported a position in EIDX in Q2 2020 and held it in 2 quarters. The position peaked at $4.77M in Q2 2020. 121 funds tracked by Wall St. Rank hold EIDX as of Q4 2020.

  • Ikarian Capital reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Ikarian Capital sold 63,011 Eidos Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $3.18M.
  • Ikarian Capital first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Ikarian Capital's Eidos Therapeutics, Inc. Common Stock position peaked at $4.77M in Q2 2020.
  • 121 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.